No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week. Read ...

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...

Aktis Oncology Inc. (NASDAQ:AKTS) drew strong investor demand in its Nasdaq debut, with shares trading at $22.91 as of 12:19 ...

Vida Ventures ("Vida"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a ...

Clinical-stage biotech Aktis Oncology (AKTS), which counts Eli Lilly (LLY) among its partners, traded sharply higher after ...

Investing.com -- Aktis Oncology shares began trading at $27 on the Nasdaq Global Market Friday, marking a 50% jump from their initial public offering price of $18 per share.

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

Merck is in talks to buy cancer drug developer Revolution Medicines in a deal that may be worth $28 billion to $32 billion ...

Mark Abate says you would have to be asleep to not see that consolidations are rampant in the world of employee benefits.

Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...